Organon & Co. (NYSE:OGN) Hits New 12-Month High – Should You Buy?

Shares of Organon & Co. (NYSE:OGN) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $13.78 and last traded at $13.7750, with a volume of 4872488 shares. The stock had previously closed at $13.78.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Five investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $11.40.

Organon & Co. Stock Down 0.0%

The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44. The business’s fifty day moving average price is $13.62 and its two-hundred day moving average price is $11.38. The stock has a market capitalization of $3.62 billion, a PE ratio of 17.89, a price-to-earnings-growth ratio of 1.28 and a beta of 1.52.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.’s payout ratio is presently 10.39%.

Institutional Investors Weigh In On Organon & Co.

A number of institutional investors and hedge funds have recently modified their holdings of OGN. Royal Bank of Canada raised its position in Organon & Co. by 53.4% during the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock worth $5,374,000 after buying an additional 125,648 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Organon & Co. by 126.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock valued at $21,370,000 after acquiring an additional 801,307 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Organon & Co. by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock valued at $15,530,000 after acquiring an additional 26,640 shares during the last quarter. Focus Partners Wealth increased its stake in shares of Organon & Co. by 33.2% in the first quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock worth $832,000 after acquiring an additional 13,925 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Organon & Co. during the second quarter worth $107,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.